EDIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Editas Medicine Inc (EDIT) is not a strong buy for a beginner, long-term investor at this moment. The stock is currently in a downtrend with weak financial performance and no significant positive catalysts to support a strong recovery. While hedge funds are buying, the technical indicators suggest overbought conditions, and the company's financials and lack of recent news do not provide a compelling case for immediate investment.
The MACD histogram is positive but contracting, indicating weakening bullish momentum. RSI is at 88.017, signaling overbought conditions. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock has faced consistent price declines recently. Key support is at 2.637, and resistance is at 3.435.
Hedge funds are significantly increasing their positions in the stock, with a 500.44% increase in buying activity over the last quarter. Analysts have raised price targets, with Evercore ISI setting a target of $15 and JonesResearch upgrading the stock to Buy with an $8 target.
The stock is in a downtrend with a -0.59% regular market change and a -2.98% post-market change. Financial performance in Q4 2025 was weak, with revenue dropping -19.16% YoY, net income down -87.62% YoY, and EPS declining -89.09% YoY. No recent news or congress trading data is available to indicate positive momentum.
In Q4 2025, revenue dropped to $24.74M (-19.16% YoY), net income fell to -$5.62M (-87.62% YoY), and EPS decreased to -$0.06 (-89.09% YoY). Gross margin remained stable at 100%. Overall, the financials indicate significant challenges in growth and profitability.
Analysts are cautiously optimistic. Evercore ISI raised the price target to $15 from $13 and maintained an Outperform rating. JonesResearch upgraded the stock to Buy from Hold with an $8 price target, citing progress on EDIT-401, a gene-editing therapy expected to launch in 2031.
